ArticleBulletin of experimental biology and medicine2025
Comparative Assessment of Pharmacokinetic Parameters of Mexidol after Intravenous Administration of Liposomal Emulsion and Aqueous Solution to Rats.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the pharmacokinetic parameters of liposomal emulsion and aqueous solution of Mexidol after intravenous injection to rats at a dose of 50 mg/kg. The concentrations of Mexidol in blood plasma and homogenates of the lungs, liver, kidneys, testes, and ovaries were measured 30, 60, 120, 240 min, 24 and 48 h after administration by HPLC. The liposomal Mexidol in contrast to its aqueous solution quickly disappeared from systemic circulation (a 5-fold decrease in plasma concentration was noted as soon as 4 h after administration) and was predominantly absorbed and retained for a longer period by the liver and lungs: after 24 h, the concentration of liposomal Mexidol exceeded that of its water-soluble form by 14.2 times in the liver and by 63% in the lungs. In the testes, the concentration of liposomal Mexidol exceeded that of its water-soluble form during the first 4 h postinjection: by 4 times after 1 h and by 2 times after 4 h, whereas in the ovarian tissues, the same concentrations were observed after administration of liposomal and water-soluble forms. In the gonadal tissues, the water-soluble form of Mexidol was retained longer than its liposomal form.
Indexed as
Identifiers
39939454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.